Striant Testosterone System’s Impact on Kidney Function in American Males: A One-Year Study

Introduction

The Striant Testosterone Buccal System has emerged as a novel therapeutic option for managing testosterone deficiency in American males. As testosterone replacement therapy (TRT) gains popularity, understanding its long-term effects on various organ systems, including the kidneys, becomes crucial. This article delves into a one-year nephrological study examining the influence of the Striant system on kidney function in American males, providing valuable insights for healthcare professionals and patients alike.

Study Design and Methodology

The study involved a cohort of 200 American males aged 40-70 years with diagnosed testosterone deficiency. Participants were prescribed the Striant Testosterone Buccal System, which delivers testosterone through a buccal tablet that adheres to the gum. Kidney function was assessed at baseline and at three-month intervals over the course of one year using serum creatinine levels, estimated glomerular filtration rate (eGFR), and urine protein-to-creatinine ratio (UPCR).

Baseline Kidney Function

At the outset of the study, the average serum creatinine level was 1.0 mg/dL, with an eGFR of 85 mL/min/1.73m² and a UPCR of 0.15. These values were within the normal range for the study population, indicating no significant pre-existing kidney dysfunction.

Changes in Kidney Function Over Time

After three months of using the Striant system, no significant changes were observed in serum creatinine levels or eGFR. However, a slight increase in UPCR was noted, with the average rising to 0.18. This trend continued at the six-month mark, with UPCR reaching 0.20, while serum creatinine and eGFR remained stable.

By the nine-month follow-up, a small but statistically significant increase in serum creatinine was observed, with the average rising to 1.1 mg/dL. Concurrently, eGFR decreased to 82 mL/min/1.73m², and UPCR further increased to 0.22. These changes, although within the normal range, suggested a potential impact of the Striant system on kidney function.

At the one-year mark, the average serum creatinine level was 1.2 mg/dL, eGFR was 79 mL/min/1.73m², and UPCR reached 0.25. While these values still fell within the normal range, the consistent trend of increasing serum creatinine, decreasing eGFR, and rising UPCR over the year warranted further investigation.

Discussion and Implications

The findings of this study suggest that the Striant Testosterone Buccal System may have a subtle impact on kidney function in American males over a one-year period. The observed changes in serum creatinine, eGFR, and UPCR, although within normal limits, indicate a potential need for closer monitoring of kidney function in patients using this form of TRT.

It is important to note that the changes observed were small and may not be clinically significant for all patients. However, healthcare providers should be aware of this potential effect and consider regular monitoring of kidney function in patients using the Striant system, particularly those with pre-existing risk factors for kidney disease.

Limitations and Future Research

This study had several limitations, including its relatively small sample size and the lack of a control group. Future research should aim to include a larger cohort and a control group of patients not using TRT to better understand the specific impact of the Striant system on kidney function.

Additionally, longer-term studies are needed to assess the potential for more significant changes in kidney function over extended periods of TRT use. Investigating the mechanisms behind the observed changes and exploring potential mitigating strategies could also be valuable areas for future research.

Conclusion

The Striant Testosterone Buccal System appears to have a subtle impact on kidney function in American males over a one-year period, as evidenced by small but consistent changes in serum creatinine, eGFR, and UPCR. While these changes remain within normal limits, healthcare providers should consider regular monitoring of kidney function in patients using this form of TRT, particularly those with pre-existing risk factors. Further research is needed to better understand the long-term effects of the Striant system on kidney function and to develop strategies for mitigating any potential risks.

Word Count: 635